Evidence map›Paper›PMID 26403783›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015

Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers.

Louisa Mezache, Bernard Paniccia, Angelique Nyinawabera, Gerard J Nuovo

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03894215 (A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034), which is not on this map. Cited by 177 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
177citing papers in PubMed, 8 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03894215 phase2terminatednot on this mapstarted 2019, after this paper: background citation

A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti- CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS

TypeinterventionalSponsorAgenus Inc.Ran2019 to 2025Enrolled211ConditionsCervical CancerArmsAGEN2034, AGEN1884
3 · Its place in the literature

Who cites it

177 citing papers in PubMed, 8 syntheses or guidelines pooled it, 306 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. SEOM-GEICO Clinical Guidelines on cervical cancer (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  15. Trial
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

117 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Louisa MezachePhylogeny Inc., Powell, OH, USA.
Bernard PanicciaPhylogeny Inc., Powell, OH, USA.
Angelique NyinawaberaPhylogeny Inc., Powell, OH, USA.
Gerard J NuovoPhylogeny Inc., Powell, OH, USA.
Phylogeny (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Programmed death ligand 1 (PD L1) expression can reduce the immune response in both infectious diseases and cancers. We thus examined PD L1 expression in cervical intraepithelial neoplasias (CINs) and cancers since they each reflect infection by human papillomavirus (HPV). PD L1 protein was not evident by immunohistochemistry in histologically normal cervical epithelia (0/55) even when adjacent to CIN or cancer. PD L1 expression was much increased in CINs (20/21=95%) and cervical squamous cell cancer (56/70=80%) and localized to the dysplastic/neoplastic squamous cells and mononuclear cells, respectively. There was also a significant increase (each P<0.001) in PD L1 detection in mononuclear cells when comparing cervical squamous cell cancers to endometrial (22/115=19%) and ovarian adenocarcinomas (5/40=13%). Co-expression analyses showed that the primary inflammatory cell that contained PD L1 was the CD8+ lymphocyte that strongly concentrated around the dysplastic CIN cells and nests of invasive squamous cancer cells. These data show that PD L1 is a solid biomarker of productive HPV infection of the cervix and that it is significantly upregulated in both the carcinoma and surrounding inflammatory cells in cervical cancer when compared with other gynecologic malignancies. This suggests that anti-PD L1 therapy may have a role in the treatment of cervical cancer.

Indexed as

AdenocarcinomaB7-H1 AntigenBiomarkers, TumorCarcinoma, Squamous CellFemaleHumansImmunohistochemistryIn Situ HybridizationPapillomavirus InfectionsUp-RegulationUterine Cervical DysplasiaUterine Cervical NeoplasmsB7-H1 AntigenBiomarkers, TumorCD274 protein, human

Identifiers

PMID26403783
OpenAlexW2342029300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.